Nevertheless, the role of IMs in the progression of EGFR mutant lung adenocarcinoma remains undefined and is not known if the reduction of IMs could have an increased effect on tumor burden reduction compared to AMs. The gene discussed is EGFR; the disease is lung adenocarcinoma.